Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 167 results for ckd

  1. Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]

    Awaiting development Reference number: GID-TA11841 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. 1.1 Evidence on the safety of electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease shows no major safety concerns. For people who are having an acute exacerbation of their chronic condition and are unable to exercise, evidence of efficacy is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit.   Find out  what standard arrangements mean on the NICE website . For people who are able to exercise, evidence on efficacy is inadequate in quality. Therefore, this procedure should only be used in the context of research. Find out  what only in research means on the NICE website .

    strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease shows no major safety concerns. For people...

    Research recommendation
    Published
    10 August 2020

  3. Delirium: prevention, diagnosis and management in hospital and long-term care (CG103)

    This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home. It also covers identifying people at risk of developing delirium in these settings and preventing onset. It aims to improve diagnosis of delirium and reduce hospital stays and complications.

    Clinical guideline
    Last updated
    18 January 2023
    View recommendations

    Sections for CG103

  4. Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)

    This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.

    NICE guideline
    Published
    6 July 2016
    View recommendations

    Sections for NG49

  5. Urinary incontinence in neurological disease: assessment and management (CG148)

    This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.

    Clinical guideline
    Last updated
    2 October 2023
    View recommendations

    Sections for CG148

  6. Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test) (HTG544)

    Evidence-based recommendations on tests to help assess risk of acute kidney injury for people being considered for critical care admission. The tests are the ARCHITECT and ALINITY i Urine NGAL assays, BioPorto NGAL test and NephroCheck test.

    HealthTech guidance
    Published
    17 June 2020
    View recommendations

    Sections for HTG544

  7. Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

    In development Reference number: GID-TA10555 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Further research is recommended to assess the effect of test-guided preventive care (see section 5.1) on clinical outcomes (such as length of stay in hospital, mortality and need for renal replacement therapy and progression to chronic kidney disease). Research should be done in children, young people and adults, but specific considerations may be needed for children and young people when care differs from that for an adult population. Studies should investigate the effects of both positive and negative test results on clinical decisions and subsequent care.

    mortality and need for renal replacement therapy and progression to chronic kidney disease). Research should be done in children, young...

    Research recommendation
    Published
    10 August 2020

  9. Everolimus for preventing organ rejection in liver transplantation (TA348)

    Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA348

  10. Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]

    In development Reference number: GID-TA10886 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. A randomised controlled trial is recommended to compare DyeVert Systems  with standard care. The aim of this research would be to address uncertainties  about whether using DyeVert Systems reduces AKI incidence and rate of renal  replacement therapy after using contrast media. This must include people with  stage 4 chronic kidney disease (with an estimated glomerular filtration rate  [eGFR] under 30 ml/min/1.73 m 2 ), who are at risk of AKI and need elective  coronary or peripheral angiography.

    after using contrast media. This must include people with stage 4 chronic kidney disease (with an estimated glomerular filtration rate...

    Research recommendation
    Published
    5 November 2021

  12. Chronic heart failure in adults: diagnosis and management (NG106)

    This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.

    NICE guideline
    Last updated
    3 September 2025
    View recommendations

    Sections for NG106

  13. Intrapartum care: existing medical conditions and obstetric complications (QS192)

    This quality standard covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. It also covers women who have had no antenatal care. It describes high-quality care in priority areas for improvement. It does not cover the antenatal and postnatal care of pregnant women with mental health conditions, hypertension in pregnancy, diabetes in pregnancy or the organisation of care for pregnant women with complex social factors.

    Quality standard
    Published
    28 February 2020
    View quality statements

    Sections for QS192

  14. Implanting a baroreceptor stimulation device for resistant hypertension (IPG533)

    Evidence-based recommendations on implanting a baroreceptor stimulation device for resistant hypertension. This involves using electrical impulses from the device that stimulate baroreceptors to help the body lower blood pressure.

    Interventional procedures guidance
    Published
    28 October 2015
    View recommendations

    Sections for IPG533

  15. Hypertension in adults (QS28)

    This quality standard covers managing hypertension in adults. It includes diagnosis and investigations, treatment and specialist referral. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    1 September 2015
    View quality statements

    Sections for QS28